Stock comparison

BRK.AvsLLY

Berkshire Hathaway Inc vs Eli Lilly and Co. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

BRK.A

Berkshire Hathaway Inc

$711,558.82

-3.36%

Financial Services$1.03TNYSE

LLY

Eli Lilly and Co

$927.03

-6.70%

Pharmaceuticals$884.0BNYSE

60-day price, rebased to 100

BRK.A -1.30% · LLY -12.77%

Round-by-round

BRK.A 4·LLY 2

EdgeBRK.A

Valuation upside

-21.00% vs -92.70% to DCF fair value

EdgeLLY

Balance-sheet strength

Altman Z 2.64 vs 15.74

EdgeLLY

Fundamental quality

Piotroski 4.00 vs 6.00 (of 9)

EdgeBRK.A

Growth + margins

Rule-of-40 2.70 vs -9.10

EdgeBRK.A

60-day momentum

-1.30% vs -12.77% price return

EdgeBRK.A

Market-cap liquidity

$1.03T vs $884.0B

Verdict

Across 6 categories, BRK.A takes the edge with 4 wins to 2. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy on BRK.A or LLY

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.